Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HAIC-GEMOX, Adebrelimab, and Lenvatinib in Resectable ICC
NCT06208462Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Propotion of treatment completion at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06208462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208462.